Get the Stockscreener App
7.46
0.67%
0.05
Grifols Sa Adr stock is traded at $7.46, with a volume of 330.56K.
It is up +0.67% in the last 24 hours and down -4.60% over the past month.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
See More
Previous Close:
$7.41
Open:
$7.51
24h Volume:
330.56K
Relative Volume:
0.71
Market Cap:
$5.08B
Revenue:
$8.62B
Net Income/Loss:
$573.80M
P/E Ratio:
10.55
EPS:
0.707
Net Cash Flow:
$680.05M
1W Performance:
+2.05%
1M Performance:
-4.60%
6M Performance:
-7.33%
1Y Performance:
-21.39%
1-Day Range:
$7.44
$7.53
1-Week Range:
$7.2839
$7.565
52-Week Range:
$6.96
$9.90
Grifols Sa Adr Stock (GRFS) Company Profile
Name
Grifols Sa Adr
Sector
Industry
Phone
-
Address
-
Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.46 | 5.08B | 8.62B | 573.80M | 680.05M | 0.707 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Resumed | Morgan Stanley | Overweight |
| Mar-12-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-12-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-16-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-18-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-08-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-19-21 | Downgrade | Barclays | Overweight → Underweight |
| Oct-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-14-21 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-20-21 | Initiated | Deutsche Bank | Hold |
| Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-11-21 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-01-20 | Upgrade | Citigroup | Sell → Neutral |
| Jun-09-20 | Downgrade | Citigroup | Neutral → Sell |
| Jun-09-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Mar-25-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-08-19 | Downgrade | Berenberg | Buy → Hold |
| Oct-11-18 | Upgrade | Berenberg | Hold → Buy |
| Jun-01-18 | Initiated | Barclays | Overweight |
| Oct-31-17 | Initiated | Citigroup | Buy |
| Jun-30-17 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-17 | Initiated | BofA/Merrill | Buy |
| Jan-03-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-09-16 | Upgrade | Berenberg | Hold → Buy |
| Jan-04-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-02-15 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-20-15 | Downgrade | Berenberg | Buy → Hold |
| Apr-28-15 | Downgrade | Berenberg | Buy → Hold |
View All
Grifols Sa Adr Stock (GRFS) Latest News
Grifols, S.A. (GRF.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance Singapore
Grifols, S.A. - Reuters
Grifols stock trades below recent highs as valuation focus grows - ad-hoc-news.de
Grifols SA Lobbying Profile, 2024 - OpenSecrets
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Grifols stock edges lower as investors weigh recent earnings and valuation - ad-hoc-news.de
Grifols SA Lobbyists, 2024 - opensecrets.org
Grifols SA Lobbying Profile, 2020 - OpenSecrets
Operating margin % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Return on invested capital % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Return on equity % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
Price to earnings ratio of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView
G0F Forecast — Price Target — Prediction for 2027 - TradingView
G0F Stock Price and Chart — HAM:G0F - TradingView
Grifols stock holds below $8 as half-year 2026 earnings highlight margin progress - ad-hoc-news.de
Grifols stock holds in single digits as Q2 2026 earnings miss consensus by a small margin - Ad-hoc-news.de
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
Grifols Up Over 6%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk - Moomoo
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - tradingview.com
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency - barchart.com
Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48Insider Buying Alerts - vinanet.vn
Grifols, S.A. Class A Revenue Breakdown – BME:GRF - TradingView
Grifols (GRFS) reshapes board, Audit and Strategy Committees - Stock Titan
Grifols shares jump after Q2 results exceed expectations - Investing.com
Grifols, S.A. Sponsored ADR Class A Revenue Breakdown – MUN:G0F - TradingView
Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Grifols (GRFS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ... - finance.yahoo.com
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols SA expected to post earnings of 24 cents a shareEarnings Preview - TradingView
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Grifols, S.A. Class A – BME:GRF - TradingView
GRFSGrifols SA ADR Options - Finviz
GRFSGrifols SA ADR Volatility & Greeks - Finviz
GRFSGrifols SA ADR Volatility & Greeks - Finviz
GRFSGrifols SA ADR Latest SEC Filings - Finviz
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
GRFSGrifols SA ADR Options - Finviz
GRFSGrifols SA ADR Forecast, Target Price - Finviz
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols Sa Adr Stock (GRFS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):